119 related articles for article (PubMed ID: 38423227)
21. Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A.
Jeong S; Nguyen PD; Desta Z
Antimicrob Agents Chemother; 2009 Feb; 53(2):541-51. PubMed ID: 19029318
[TBL] [Abstract][Full Text] [Related]
22. Herb-drug interaction between Styrax and warfarin: Molecular basis and mechanism.
Zhang F; Huang J; He RJ; Wang L; Huo PC; Guan XQ; Fang SQ; Xiang YW; Jia SN; Ge GB
Phytomedicine; 2020 Oct; 77():153287. PubMed ID: 32739573
[TBL] [Abstract][Full Text] [Related]
23. Assessment of the
Giri P; Gupta L; Singh S; Patel N; Srinivas NR; Srivastva BK; Desai RC; Patel PR
Xenobiotica; 2019 Oct; 49(10):1164-1172. PubMed ID: 30488748
[TBL] [Abstract][Full Text] [Related]
24. Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation.
Chang Y; Fang WB; Lin SN; Moody DE
Basic Clin Pharmacol Toxicol; 2011 Jan; 108(1):55-62. PubMed ID: 20825389
[TBL] [Abstract][Full Text] [Related]
25. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
[TBL] [Abstract][Full Text] [Related]
26. In vitro inhibition and induction of human liver cytochrome p450 enzymes by milnacipran.
Paris BL; Ogilvie BW; Scheinkoenig JA; Ndikum-Moffor F; Gibson R; Parkinson A
Drug Metab Dispos; 2009 Oct; 37(10):2045-54. PubMed ID: 19608694
[TBL] [Abstract][Full Text] [Related]
27. Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis.
Atkinson A; Kenny JR; Grime K
Drug Metab Dispos; 2005 Nov; 33(11):1637-47. PubMed ID: 16049126
[TBL] [Abstract][Full Text] [Related]
28. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen.
Koenigs LL; Peter RM; Thompson SJ; Rettie AE; Trager WF
Drug Metab Dispos; 1997 Dec; 25(12):1407-15. PubMed ID: 9394031
[TBL] [Abstract][Full Text] [Related]
29. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies.
Wang L; Zhang D; Raghavan N; Yao M; Ma L; Frost CE; Maxwell BD; Chen SY; He K; Goosen TC; Humphreys WG; Grossman SJ
Drug Metab Dispos; 2010 Mar; 38(3):448-58. PubMed ID: 19940026
[TBL] [Abstract][Full Text] [Related]
30. In vitro inhibition of human liver cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) enzymes by rose bengal: system-dependent effects on inhibitory potential.
Kazmi F; Haupt LJ; Horkman JR; Smith BD; Buckley DB; Wachter EA; Singer JM
Xenobiotica; 2014 Jul; 44(7):606-14. PubMed ID: 24405273
[TBL] [Abstract][Full Text] [Related]
31. AM-2201 Inhibits Multiple Cytochrome P450 and Uridine 5'-Diphospho-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes.
Kim JH; Kwon SS; Kong TY; Cheong JC; Kim HS; In MK; Lee HS
Molecules; 2017 Mar; 22(3):. PubMed ID: 28287454
[TBL] [Abstract][Full Text] [Related]
32. In vitro metabolism and drug interaction potential of a new highly potent anti-cytomegalovirus molecule, CMV423 (2-chloro 3-pyridine 3-yl 5,6,7,8-tetrahydroindolizine I-carboxamide).
Bournique B; Lambert N; Boukaiba R; Martinet M
Br J Clin Pharmacol; 2001 Jul; 52(1):53-63. PubMed ID: 11453890
[TBL] [Abstract][Full Text] [Related]
33. In vitro inhibitory effects of pristimerin on human liver cytochrome P450 enzymes.
Hao X; Yuan J; Xu Y; Wang Z; Hou J; Hu T
Xenobiotica; 2018 Dec; 48(12):1185-1191. PubMed ID: 28385095
[TBL] [Abstract][Full Text] [Related]
34. In Vitro Inhibition of Human CYP450s 1A2, 2C9, 3A4/5, 2D6 and 2E1 by Grandisin.
Habenschus MD; Moreira FL; Lopes NP; de Oliveira ARM
Planta Med; 2017 May; 83(8):727-736. PubMed ID: 28073119
[TBL] [Abstract][Full Text] [Related]
35. In vitro inhibitory effects of dihydromyricetin on human liver cytochrome P450 enzymes.
Liu L; Sun S; Rui H; Li X
Pharm Biol; 2017 Dec; 55(1):1868-1874. PubMed ID: 28614988
[TBL] [Abstract][Full Text] [Related]
36. Potent inhibitory effect of alpha-viniferin on human cytochrome P450.
Sim J; Jang HW; Song M; Kim JH; Lee SH; Lee S
Food Chem Toxicol; 2014 Jul; 69():276-80. PubMed ID: 24769006
[TBL] [Abstract][Full Text] [Related]
37. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes.
Yao HT; Chang YW; Lan SJ; Chen CT; Hsu JT; Yeh TK
Life Sci; 2006 Nov; 79(26):2432-40. PubMed ID: 16978661
[TBL] [Abstract][Full Text] [Related]
38. Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450.
Zhao XJ; Yokoyama H; Chiba K; Wanwimolruk S; Ishizaki T
J Pharmacol Exp Ther; 1996 Dec; 279(3):1327-34. PubMed ID: 8968357
[TBL] [Abstract][Full Text] [Related]
39. Development and validation of a liquid-chromatography high-resolution tandem mass spectrometry approach for quantification of nine cytochrome P450 (CYP) model substrate metabolites in an in vitro CYP inhibition cocktail.
Dinger J; Meyer MR; Maurer HH
Anal Bioanal Chem; 2014 Jul; 406(18):4453-64. PubMed ID: 24830396
[TBL] [Abstract][Full Text] [Related]
40. Effects of artemisinin antimalarials on Cytochrome P450 enzymes in vitro using recombinant enzymes and human liver microsomes: potential implications for combination therapies.
Ericsson T; Sundell J; Torkelsson A; Hoffmann KJ; Ashton M
Xenobiotica; 2014 Jul; 44(7):615-26. PubMed ID: 24400699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
